New prostate cancer treatment shows promise and 'could help 40 per cent'

A double-pronged attack on advanced prostate cancer could help treat as many as two in five patients with late-stage disease, ...
The Manila Times

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells ...